Scarica l'app Stockscreener
3.62
0.82%
-0.03
Pre-mercato:
3.68
0.06
+1.66%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Eyepoint Inc Borsa (EYPT) Ultime notizie
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why - Stocktwits
EyePoint, Inc. (EYPT) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review
EyePoint faces securities fraud probe after Pha... - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - PR Newswire
EyePoint Pharmaceuticals Inc (EYPT) Stock Price Target & Forecast - TradingKey
EyePoint, Inc. (EYPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
EyePoint Pharmaceuticals stock holds near its yearly range - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Encourages EyePoint, Inc. (EYPT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against EyePoint, Inc. (EYPT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
EyePoint, Inc. (EYPT) Stock Analysis: Exploring A Potential 549% Upside For Investors - DirectorsTalk Interviews
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - kalkine.ca
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against EyePoint, Inc. (EYPT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
EYPT Q2 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Edge HigherRevenue Breakdown Analysis - careplusvn.com
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
EyePoint Inc at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against EyePoint, Inc. (EYPT) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT) - The Globe and Mail
EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead - Investing.com Canada
EyePoint posts updated presentation showing LUGANO Phase 3 DURAVYU topline results, NDA path to H1 2027 - TradingView
Eye drug cuts injections 42% in EyePoint (EYPT) trial but misses its main goal - Stock Titan
EyePoint Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Transcript : EyePoint, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com India
INVESTIGATION ALERT: Investigation Launched Into EyePoint, Inc. (EYPT), Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - Barchart.com
Investment firm discloses double-digit stake in EyePoint (EYPT) - Stock Titan
EyePoint's stock plunges 66% after failed Phase 3 trial for wet AMD treatment. - Pluang
Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire
EYPT News | EYEPOINT INC (NASDAQ:EYPT) - ChartMill
EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm - GlobeNewswire Inc.
EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO - finance.yahoo.com
EyePoint faces securities fraud probe after tri... - Pluang
Eyepoint Pharmaceuticals Inc (EYPT) Peer Comparison – Compare with Others - Value Research
EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals - GlobeNewswire
EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
EyePoint stock drops as TD Cowen downgrades (EYPT:NASDAQ) - Seeking Alpha
TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20 - marketscreener.com
EyePoint Announces Upcoming Investor Conference and Retina Society Presentations - Quiver Quantitative
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting - marketscreener.com
TD Cowen downgrades EyePoint stock to Hold on trial concerns By Investing.com - Investing.com Canada
TD Cowen downgrades EyePoint stock to Hold on trial concerns - investing.com
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm - Sahm
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law - financialcontent.com
Eyepoint Pharmaceuticals Inc (EYPT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
EyePoint After LUGANO: Primary Endpoint Miss, Asymmetric Risk-Reward (NASDAQ:EYPT) - Seeking Alpha
EyePoint Pharmaceuticals (EYPT) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
EyePoint (EYPT) CFO moves 139K shares into family and annuity trusts - Stock Titan
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70% - The Economic Times
Taxes of EyePoint, Inc. – HAM:PV3B - TradingView
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) - Business Wire
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):